Form 4: Ionis Pharmaceuticals Executive Sells Shares
Statement of Changes in Beneficial Ownership
Holly B. Kordasiewicz, EVP and Chief Development Officer at Ionis Pharmaceuticals, sold 362 shares of common stock on July 7, 2026, valued at $84.3 per share, as part of a pre-established trading plan.
Summary
- Holly B. Kordasiewicz, Executive Vice President and Chief Development Officer of Ionis Pharmaceuticals, reported a transaction involving the sale of company stock.
- The transaction involved the sale of 362 shares of common stock on July 7, 2026.
- The sale was executed at a price of $84.3 per share.
- The total value of the transaction was approximately $30,500.
- These shares were sold as part of a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
- Following the transaction, Kordasiewicz beneficially owns 22,096 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While an executive sale can be a negative signal, the transaction was executed under a pre-arranged Rule 10b5-1 plan, indicating a planned divestiture rather than a reaction to company performance.
Negatives
- An executive sold company stock, which could be perceived negatively by the market, although it was conducted under a pre-arranged trading plan.
Future Outlook
The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.
Industry Context
StockSavvy.ai notes that insider stock sales, even when conducted under a Rule 10b5-1 plan, can sometimes lead to investor scrutiny. However, the existence of such a plan suggests a pre-determined strategy for managing personal holdings, mitigating concerns about opportunistic selling based on non-public information.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Rule 10b5-1 Trading Plan | The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 03/13/2026 | This plan allows for pre-scheduled stock sales, providing a defense against insider trading allegations and demonstrating a structured approach to personal financial management by executives. |
Stakeholder Impact
- Shareholders: May interpret the sale as a sign of reduced confidence by management, although the Rule 10b5-1 plan mitigates this concern. The direct ownership of 22,096 shares by Kordasiewicz still indicates significant alignment with the company's success.
Key Dates
| Date | Description |
|---|---|
| 03/13/2026 | Date Rule 10b5-1 Trading Plan was adopted by Holly B. Kordasiewicz. |
| 07/07/2026 | Date of the transaction (sale of common stock). |
| 07/09/2026 | Date of signature on the Form 4 filing. |
Keywords
Ionis Pharmaceuticals, IONS, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Holly B. Kordasiewicz, Executive Officer, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.